Kornimate/medical-research-clean huggingface dataset:
study evaluating prophylaxis treatment & characterizing efficacy, safety, & pk of b-domain deleted recombinant fviii

Conditions: Hemophilia A

Summary: the purpose of this research study is to determine the effectiveness, safety, and pharmacokinetics (pk) of moroctocog alfa (af-cc) in previously treated subjects, who are younger than 6 years of age, with severe or moderately severe hemophilia a.


Eligibility criteria:
inclusion criteria: * male subjects, aged less than 6 years, with moderately severe to severe hemophilia a. * a negative fviii inhibitor titer at screening, and a medical history negative for a past fviii inhibitor. * at least 20 exposure days to any fviii replacement product. * adequate hepatic and renal function * cd4 count \> 400 cells/ul, and if receiving antiviral therapy must be on a stable regimen additional criteria for subjects participating in the pk assessment: * male subjects as described immediately above except they must have a fviii activity of less than or equal to 1% confirmed by the central laboratory screening test * age \< 6 years at time of pk assessment. * the subject's size is sufficient to permit pk-related phlebotomy. * the subject is able to comply with the procedures conducted during the pk assessment, including a mandatory 72-hour washout period preceding the pk assessment. exclusion criteria: * a history of fviii inhibitor. * presence of a bleeding disorder in addition to hemophilia a. * treatment with any investigational drug or device within 30 days before the time of signing the informed consent form. * major or orthopedic surgery planned to occur during the course of the study. * regular (e.g., daily, every other day) use of antifibrinolytic agents or medications known to influence platelet function such as aspirin or certain nonsteroidal anti-inflammatory drugs (nsaids), or regular, concomitant therapy with immunomodulating drugs (e.g., intravenous immunoglobulin \[ivig\], routine systemic corticosteroids). * known hypersensitivity to hamster protein.
nutritional intervention for geriatric hip fracture patients

Conditions: Hip Fractures

Summary: this is a randomized controlled, observer blinded trial to study the beneficial effect of nutritional supplementation in elderly hong kong patients after hip fracture surgery during rehabilitation and at 4 weeks follow up. the control group will receive calcium and vitamin d supplementation whereas the intervention group will receive a moderately high dose protein nutritional supplementation in addition to vitamin d and calcium. both groups undergo the same rehabilitation program and dietary counseling before discharge. they are followed up 4 weeks after discharge or completion of supplementation. the outcome parameters are nutritional parameters and rehabilitation outcomes.


Eligibility criteria:
inclusion criteria: * age 60 years or older * recent low impact osteoporotic fracture of the proximal femur surgically repaired within 4 weeks before recruitment exclusion criteria: * patients who require tube feeding * patients in unstable medical condition * body mass index (bmi) ≧ 25 * malignancy * conditions with contraindication for high protein diet * mentally incapacitated and inability to communicate or understand the consent.

Keywords: nutritional support rehabilitation outcomes
breathing exercises and adhesive capsulitis

Conditions: Adhesive Capsulitis

Summary: the purpose of this study was to determine the effects of abdominal breathing exercises on pain, sleep quality and quality of life with adhesive capsulitis patients. the 41 adhesive capsulitis patients, 29 women and 12 men aged between 40-65 years, had divided into two groups by simple random sampling. in the study group, abdominal breathing exercise training was applied to routine physiotherapy program, in the control group routine physiotherapy program was applied for 8 weeks. individuals were assessed for lung function test, range of motion, pain, sleep quality and quality of life. first assesment were performed at the beginning of treatment, 2nd assesment were performed at the end of 8 th week.

pain in the early stages of adhesive capsulitis leads to many symptoms such as sleeping problems. breathing exercises also began to take place among the applications towards pain. abdominal respiration is considered the easiest method to reveal relaxation response. slow breathing increases parasympathetic activity in the body and reduces sympathetic activity. this is the first and fundamental step of real healing. the reduction of pro-inflammatory markers with respiratory exercises suggests that respiratory exercises are effective in inflammation. on study group; hotpack was applied for 15 minutes and tens was applied for 15 minutes and ultrasonics for 5 minutes. then, scapular mobilization and passive stretching exercises were applied in 10 sets of 3 sets (flexion, abduction, internal and external rotation) to increase joint range of motion by physiotherapist. then abdominal respiratory exercise training was given 3 times a week as 30 sets of 3 times a week and patients were treated for 8 weeks. for the control group; hotpack was applied for 15 min and tens was applied for 15 min and ultrasonics for 5 min. then scapular mobilization and passive stretching exercises were applied for 8 weeks in 10 sets of 3 sets (flexion, abduction, internal and external rotation) to increase joint range of motion by physiotherapist.

Eligibility criteria:
inclusion criteria: * those who have received an adhesive capsulitis diagnosis, * those in the age range 40-65 exclusion criteria: * those who take medicine for pain, * those with a primary sleep problem, * those with respiratory system disease, * those with cognitive problems, * non-volunteer

Keywords: adhesive capsulitis breathing exercises pain sleep quality quality of life
abdominoplasty with ventral hernia repair versus hernioplasty .

Conditions: Abdominal Hernia

Summary: comparison between hernioplasty alone versus concomitant abdominoplasty with ventral hernia repair regarding efficacy and post-operative recurrence of hernia.

ventral hernias are very common and do present a challenge because of the risk of recurrence. ventral hernias of the abdomen are defined as a non-inguinal, nonhiatal defect in the fascia of the abdominal wall. annually, there are about 350,000 ventral hernia operations. the repair of these abdominal wall defects is a common surgery performed by general surgeons. surgery is typically recommended for individuals with acceptable operative risk, symptomatic hernias, or those at elevated risk of developing complications from a hernia. they can affect an individual's quality of life and can lead to hospitalizations and even death in some cases.\[1\]\[2\]\[3\] common causes of acquired ventral hernias include previous surgery causing an incisional hernia, trauma, and repetitive stress on naturally weak points of the abdominal wall. these naturally occurring weak points in the abdominal wall include the umbilicus, semilunar line, ostomy sites, bilateral inguinal regions, and esophageal hiatus. obesity is a large component of hernias as well because it stretches the fascia of the abdomen causing it to weaken. specifically, the action of repetitive weight gain and loss leads to weakening.\[4\] reported recurrence rates after vhr in the literature vary widely and range from 2.7% to 20% for primary ventral hernia (umbilical and epigastric) to 32-37% for incisional hernia repairs, depending on the series in question. (5) abdominoplasty can be performed in combination with hernia repair in patients with ventral hernias, especially when associated with large midline ventral hernias, diastasis of recti and the associated laxity and abdominal shape deformity, represent aesthetic and functional problems for the patients. so, the surgical treatment of both pathologies at the same time is highly recommended if the patient's general condition permits. this can be achieved by a comprehensive technique incorporating abdominoplasty performed by a transverse lower abdominal incision into any of the hernia repair techniques.(6) the procedure continues to become increasingly popular, and this is attributed to the increasing rates of obesity and subsequent use of weight loss surgery aim(s) of the research (50 words max): is to compare the outcome and efficacy of the combined procedure of (abdominoplasty and hernioplasty) to hernioplasty alone according to rate of post operative recurrence of hernia .

Eligibility criteria:
inclusion criteria: * patients with age more than 20 years and less than 60 years old. female patients. patients having ventral hernias with bm more than 25 kg/m2. patients with floppy abdomen patients with divercation of recti patients with an (asa) classification of 3 or less with no history of dm or other major comorbidities as cardiopulmonary, hepatic, or renal impairment.exclusion criteria: -

Keywords: ventral hernia abdominoplasty hernioplasty
studying tumor tissue samples from patients who have undergone surgery for localized kidney cancer

Conditions: Kidney Cancer

Summary: rationale: studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research study is looking at tumor tissue samples from patients who have undergone surgery for localized kidney cancer.

objectives: * to identify consistent patterns of vegf expression, e-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity as predictive factors in the development of aggressive tumor behavior in tumor tissue samples from patients with localized clear cell renal cell carcinoma. outline: previously collected tumor tissue samples are examined by immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., vegf expression, e-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity). samples are compared to positive tissue controls (i.e., vegf- tonsil; e- cadherin-normal breast or endometrium; mmp2- placenta) and a negative control (i.e., isotype matched normal serum) to identify consistent patterns of expression/activity of these factors. levels of expression are quantified as 5-level scores (0 to 4 scale) and differences between any two areas of a tumor are analyzed.

Eligibility criteria:
disease characteristics: * tumor tissue samples from patients who recently underwent nephrectomy or partial nephrectomy for clear cell renal cell carcinoma * harvested from the superior, inferior, left lateral, right lateral, and central portions of resected or discarded tumor measuring 4 cm or less * localized disease (pt1a, n0-nx, m0) patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: stage i renal cell cancer stage iii renal cell cancer recurrent renal cell cancer clear cell renal cell carcinoma childhood renal cell carcinoma
fondaparinux for the treatment of heparin-induced thrombocytopenia (hit)

Conditions: Heparin-Induced Thrombocytopenia

Summary: the purpose of this study is to determine how safe and effective fondaparinux is in treating patients with suspected or confirmed heparin-induced thrombocytopenia (hit).

currently, standard treatment of hit involves the transition from a direct thrombin inhibitor (a type of anticoagulant or "blood thinner") to warfarin, a different type of anticoagulant. direct thrombin inhibitors (dtis) require iv administration and frequent blood draws for dose adjustments, which can lead to prolonged hospitalization. dtis also affect blood test measurements, making it difficult to determine proper dosages of warfarin. fondaparinux is a drug that is approved by the fda for the treatment of blood clots in deep veins and in the lungs. fondaparinux is not fda approved for the treatment of hit. however, an increasing number of doctors are using fondaparinux instead of dtis to treat hit. although fondaparinux appears to be more convenient and predictable than dti medications, more research is needed to support its use as a treatment for hit.

Eligibility criteria:
inclusion criteria: * high risk for hit based on "four ts score" of 6 or more exclusion criteria: * pulmonary emboli at the time of enrollment * arterial thrombosis at the time of enrollment * limb threatening phlegmasia cerulea dolens at the time of enrollment * calculated creatinin clearance less than 50 ml/hr * platelet count less than 50 * weight less than 50 kg * pregnancy * allergy to fondaparinux * bacterial endocarditis * history of neuraxial anesthesia and post-operative indwelling epidural catheter * active major bleeding (hemodynamically significant or requiring transfusions) * inability to give informed consent

Keywords: heparin-induced thrombocytopenia thrombocytopenia hit thrombosis blood clot blood thinner anticoagulant heparin warfarin fondaparinux arixtra
comparative effects of different stretching protocols on performance enhancement in racquet sports.

Conditions: Sport Injury; Sport Performance

Summary: this study intends to compare the effects of static stretching protocols with dynamic stretching protocols on racquet sports players to find out how these protocols affect their performance.

in this study, two groups will be formed to find out the effects of static and dynamic stretching protocols on racquet sports players over a course of 6 weeks. one group is given the static stretching protocol, and the other group is given the dynamic stretching protocol, and at the end of the 1st, 3rd, and 6th weeks, readings are taken to compare the effects of these techniques on the performance of the subjects enrolled in this study. a total of 52 participants will be involved, and the groups will be divided into 26, 26 each. data will be analyzed through spss version 21.

Eligibility criteria:
inclusion criteria: * males. * age 20- 40 years. * amateur active players with at least 1 year of regular experience. * free from any musculoskeletal injuries or conditions affecting participation. * willing to provide written informed consent. exclusion criteria: * players with ongoing or recent (\<3 months) musculoskeletal injuries. * those with chronic conditions (e.g., arthritis, cardiovascular issues) affecting physical activity. * those suffering with any medical condition that affects their performance. * participants who are currently following a specialized stretching regimen outside regular squash warm-ups. * use of medications that could affect muscle function or perception during the study.

Keywords: static stretching dynamic stretching racquet sports performance squash badminton
intelligent and adaptive control applied to powered walkers

Conditions: Cerebral Palsy

Summary: the research is towards an advanced control and computer learning strategy that will intelligently drive a powered walker for people with walking disabilities. the aim of the control strategy is to provide powered assistance that optimally reduces the metabolic cost of walking. the goal of the proposed intelligent walker is to reduce the workload of walking, keeping this population walking longer, providing critical exercise, continued muscle development and improved quality of life.


Eligibility criteria:
inclusion criteria: typically developed subjects: • no walking disabilities subjects with cp: * diagnosed with spastic cp * gmfcs level ii-iii * ages 5-25 inclusive * no surgeries in last 6 months * able to ambulate 40ft unaided (excluding walker) * understand and follow commands exclusion criteria: typically developed subjects: • observed intramuscular pathology subjects with cp: * mental retardation * severe uncontrolled seizures * leg or foot surgery in last 12 months * surgery or significant injury in last 6 months affecting * walking ability * inability to ambulate unassisted (other than walker) 40ft * without stopping to rest * inability to understand or follow commands
ccta to optimize diagnostic yield of invasive angiography with ai

Conditions: Coronary Artery Disease

Summary: coronary artery disease (cad) is a leading cause of death. the gold-standard test used to diagnose cad is invasive coronary angiography (ica). however, nearly half the patients who receive ica are found to have no disease or non-significant disease. this means that while they receive a diagnosis, they do not receive any therapeutic benefit. this is concerning because ica is expensive and it carries a risk to patients. a non-invasive diagnostic test, cardiac computed tomographic angiography (ccta), has been shown to be as effective as ica at diagnosing cad in the right patient population, while being less expensive and less risky for patients. an optimal solution would involve screening to identify which patients are good candidates for ccta vs. which should receive ica. this screening tool could be used in a triage pathway to ensure that every patient gets the test that is best for them. the investigators have used artificial intelligence (ai) to develop a model for determining which patients should receive ica vs. which should receive ccta. the investigators have also developed a triage pathway to direct patients to the most appropriate test. the investigators now plan to evaluate the ai tool combined with the triage pathway through a clinical trial at hamilton health sciences and niagara health. this model of care will reduce risk to patients, reduce wait times for ica and reduce costs to the health care system.


Eligibility criteria:
inclusion criteria patients are eligible if they: 1. are ≥18 years of age; 2. are referred for non-urgent (elective) outpatient ica; 3. have an indication for ica that includes 'rule out cad', 'cardiomyopathy', or 'stable cad'; and 4. are able to provide informed consent in english. exclusion criteria patients are ineligible if they have: 1. received a prior high-quality coronary computed tomographic angiography (ccta) within the last 5 years; 2. atrial fibrillation; 3. known severe renal dysfunction (gfr \<35); 4. planned non-coronary cardiac surgery; 5. any prior obstructive cad, acute coronary syndrome, percutaneous coronary intervention, or coronary artery bypass graft; or 6. known severe coronary artery calcification (calcium score \>1000).

Keywords: artificial intelligence (ai) coronary angiography coronary computed tomography angiography
covid-19 in cancer patients: evaluation of clinical course and impact on oncological care including biobanking

Conditions: Cancer; COVID

Summary: the covidhelp study will prospectively evaluate the yet unknown clinical course of the covid-19 infection in cancer patients and document the impact of potential infrastructural limitations on cancer care of covid-19 positive patients. all patients consenting will provide peripheral blood samples for prospective biobanking with the aim of investigating immune response and immunity against covid-19.

based on patients, who are treated in the university cancer center hamburg (ucch) and its contracted partner network, which comprises all cancer treating departments at the university medical center of hamburg-eppendorf (uke), as well as 19 office-based oncologists and 20 surrounding hospitals, recruitment for the study will be done as follows: (i) as a cancer patient during regular aftercare appointments who reports a current or past covid-19 infection. (ii) as an acute covid-19 patient who reports a prevalent cancer diagnosis data will be collected as available from routine clinical care and includes demographic and biometric data, medical history, baseline data at inclusion as well as inpatient and intensive care unit admissions. upon consent, patients will provide peripheral blood samples at time of inclusion and after 6 month. recruitment is limited to a one-year period (april 2020 - april 2021).

Eligibility criteria:
key inclusion criteria: * known diagnosis of cancer * known diagnosis of covid-19 infection * age ≥ 18 years * signed informed consent key exclusion criteria: • refusal of participation
safety and efficacy of subretinal transplantation of clinical human embryonic stem cell derived retinal pigment epitheliums in treatment of retinitis pigmentosa

Conditions: Retinitis Pigmentosa

Summary: this project intends to transplant a clinical level human embryonic stem cells derived retinal pigment epithelium into subretinal space to treat eetinitis pigmentosa(rp) diseases. through the statistical analysis edtrs, bcva, oct, erg, fluorescein angiography, ophthalmic ab ultrasound changes between before and after the treatment to assess the efficacy and safety 0f rpe transplants to treat rp disease.

this project intends to transplant a clinical level human embryonic stem cells derived retinal pigment epithelium into subretinal space to treat eetinitis pigmentosa(rp) diseases. through the statistical analysis edtrs, bcva, oct, erg, fluorescein angiography, ophthalmic ab ultrasound changes between before and after the treatment to assess the efficacy and safety 0f rpe transplants to treat rp disease.

Eligibility criteria:
inclusion criteria: * age above 18 and under 80 years of age, both gender, in good health. * clinical diagnosis of retinitis pigmentosa, the results of eye electrophysiological examination accord with retinitis pigmentosa. * the bcva of target eye will not be better than 20/400. * the bcva of contralateral eye is not worse than 20/400. * diopter is smaller than 8.00 d, axial 28 mm or less. * voluntary as test subjects, signed informed consent, regular follow-up will be effected according to the specified time. exclusion criteria: * subject with other additional retinal diseases, like diabetic or hypertensive retinopathy vascular diseases. * target eye ever have had a eye surgery; * subject with active serious diseases of the digestive system, liver kidney impairment (alt/ast) \> 1.5 or any known liver disease, creatine \> 1.3 mg/dl) and/serious temic diseases, such as cardiovascular tem, respiratory tem, nervous tem, endocrine tem urogenital tem diseases, etc.), the history of malignancy; * have been ready for pregnancy during test, are lactating women; * ready to birth of men during the test; * subject with any immunodeficiency; * subject in the immunosuppressive therapy in the current; * subject with the tacrolimus or other large ring lactone class drug allergies; * participate in any clinical subjects in nearly six months; * has a history of alcohol or illicit drug abuse; * poor adherence to complete studies; * researchers believe that there may be an increased risk subjects or interfere with the clinical trials of any situation (such as when a patient is prone to mental tension, depression, mental illness, cognitive dysfunction, etc.).
a phase 2 dose-finding study of ts-172 in hyperphosphatemia patients on hemodialysis

Conditions: Hyperphosphatemia Patients on Hemodialysis

Summary: a phase 2, randomized, placebo-controlled, double-blind, dose-finding study of ts-172 in hyperphosphatemia patients on hemodialysis


Eligibility criteria:
inclusion criteria: 1. hyperphosphatemia patients (outpatients) with chronic kidney disease receiving hemodialysis (hd or hdf) 3 times a week for at least 12 weeks prior to visit 1 (week -4) 2. patients aged ≥18 to \<80 years at the time of obtaining informed consent 3. patients with a serum phosphorus concentration of ≥ 3.5 mg/dl and ≤ 6.0 mg/dl at visit 1 (week -4) exclusion criteria: 1. patients with confirmed serum intact pth concentration \>500 pg/ml from visit 1 (week -4) to visit 5 (week 0) 2. patients with serum phosphorus concentration ≥ 10.0 mg/dl from visit 2 (week -3) to visit 5 (week 0) 3. patients who have undergone previous parathyroid intervention (ptx, peit, etc.)